A repertoire of biomarkers helps in detection and assessment of therapeutic response in epithelial ovarian cancer
Authors:
- 19 October 2013
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 386 (1-2) , 259-269
Abstract
In epithelial ovarian cancer (EOC), the cancer antigen 125 (CA-125) has been conventionally used to help in diagnosis and assessment of response to treatment. Currently, YKL-40 (Tyrosine–Lysine–Leucine-40) and circulating cell-free DNA are being evaluated for possession of similar ability. In this study, we aimed to assess the ability of a repertoire of potential biomarkers in detecting and assessing therapeutic response, in advanced EOC. Blood levels of CA-125, YKL-40, total cell-free DNA (CFDNA), cell-free nuclear DNA (CFnDNA), and cell-free mitochondrial DNA (CFmDNA) levels were measured in 100 untreated patients of advanced EOC from November 2009 to June 2011, and again on treatment completion from the 20 patients who appeared for follow-up analysis. Significantly, higher proportion of untreated patients had serum CA-125 >3 times upper limit of normal (ULN) (90.0 %; P < 0.0001) and plasma YKL-40 >ULN (77.0 %; P < 0.0001), both of which significantly decreased, Posttherapy. posttherapy, CFDNA (P < 0.0001), and CFnDNA (P < 0.0001) levels significantly decreased as compared to pretreatment levels. Positive and significant correlations existed between pretherapy CFDNA and CFnDNA [Spearman rho (ρ) = 1.000; P < 0.0001], and also with CFmDNA (ρ = 0.301; P = 0.002), separately between CFnDNA and CFmDNA (ρ = 0.303; P = 0.002), as well as between plasma YKL-40 and patient age (ρ = 0.353; (P < 0.0001). On treatment completion, CFDNA and CFnDNA levels showed positive and significant correlation (ρ = 1.000; P < 0.0001). Therefore serum CA-125 and plasma YKL-40 aid detection and assessment of therapeutic response, in advanced EOC. CFDNA and CFnDNA help in estimating extent of therapeutic response in advanced EOC.Keywords
This publication has 28 references indexed in Scilit:
- Combined use of biomarkers for detection of ovarian cancer in high-risk womenTumor Biology, 2010
- Ovarian cancer: the duplicity of CA125 measurementNature Reviews Clinical Oncology, 2010
- Plasma cell‐free DNA in ovarian cancerCancer, 2010
- Longitudinal monitoring of CA125 levels provides additional information about survival in ovarian cancerJournal of Ovarian Research, 2010
- Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumorsMolecular Cancer, 2009
- YKL-40, a secreted glycoprotein, promotes tumor angiogenesisOncogene, 2009
- YKL-40 tissue expression and plasma levels in patients with ovarian cancerBMC Cancer, 2009
- YKL-40 - an emerging biomarker in cardiovascular disease and diabetesCardiovascular Diabetology, 2009
- Mitochondrial DNA in serum of patients with prostate cancer: a predictor of biochemical recurrence after prostatectomyBJU International, 2008
- Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancerAnnals of Oncology, 2007